Welcome to our dedicated page for Atara Biotherape news (Ticker: ATRA), a resource for investors and traders seeking the latest updates and insights on Atara Biotherape stock.
Atara Biotherapeutics, Inc. develops allogeneic T-cell immunotherapies through an Epstein-Barr virus (EBV) T-cell platform for cancer and autoimmune disease programs. Company news centers on tabelecleucel, also referred to as tab-cel or EBVALLO, regulatory communications with the FDA, and collaboration activity with Pierre Fabre Pharmaceuticals for the EBV-positive post-transplant lymphoproliferative disease program.
Recurring updates also cover financial results, commercialization revenue, research and development spending, operational efficiency measures, milestone and royalty-related agreements, and equity-linked financing instruments such as warrants. Atara also reports on its inventory-based cell therapy approach, platform attributes that avoid T-cell receptor or HLA gene editing, and pipeline candidates including ATA3431 and ATA3219.
Atara Biotherapeutics (Nasdaq: ATRA) reported a regulatory update on tabelecleucel (tab-cel) after a Type A meeting between the FDA and partner Pierre Fabre Pharmaceuticals. The FDA agreed a prospectively specified single‑arm study using an appropriate historical control could be adequate to support a resubmitted BLA.
Pierre Fabre intends to include an updated dataset with additional patients and longer follow‑up from the pivotal Phase 3 ALLELE study; Atara will support the resubmission and expects a further regulatory update in the third quarter.
Atara Biotherapeutics (Nasdaq: ATRA) reported fourth-quarter and full-year 2025 results and operational updates on March 16, 2026. The company reported $8.5 million in cash and short-term investments at Dec 31, 2025 and $120.8 million in 2025 commercialization revenue.
Atara posted a $32.7 million net income for FY2025 and expects its current resources plus $3.0 million ATM proceeds to fund operations through year-end 2026; a Type A meeting between Pierre Fabre and the FDA on tabelecleucel is scheduled with a regulatory update anticipated in Q2 2026.
Atara Biotherapeutics (Nasdaq: ATRA) said a Type A meeting with FDA has been scheduled to discuss the Complete Response Letter for the tabelecleucel (tab-cel) Biologics License Application held by partner Pierre Fabre Pharmaceuticals. Pierre Fabre, with Atara support, will seek to address CRL points and enable a BLA resubmission using additional efficacy data collected since the original submission. Atara expects to provide a further regulatory update in the second quarter.
Atara Biotherapeutics (NASDAQ: ATRA) said partner Pierre Fabre Pharmaceuticals submitted a request for a Type A meeting with the FDA on March 3, 2026 to address the Complete Response Letter dated January 9, 2026 for tabelecleucel (tab-cel).
The briefing book reportedly argues the ALLELE study was adequate and includes updated longer-term ALLELE efficacy data, additional supportive development data, and post-marketing data from Europe intended for a potential resubmission.
Atara Biotherapeutics (Nasdaq: ATRA) amended its December 2022 Purchase and Sale Agreement with a fund managed by HealthCare Royalty to push a one-time $9.0 million milestone cash payment from June 30, 2026 to January 1, 2028.
In connection with the amendment, Atara issued a warrant for up to 400,000 common shares at an exercise price of $0.0001 per share, exercisable immediately with no expiration and subject to a beneficial ownership limit. Management cites time to address a recent CRL and to support partner Pierre Fabre on tabelecleucel regulatory work.
Pierre Fabre Pharmaceuticals (collaborating on ATRA program) announced receipt of a Complete Response Letter (CRL) from the U.S. FDA on Jan 9, 2026, stating the tabelecleucel Biologics License Application cannot be approved in its present form.
The company says the FDA acknowledged resolution of a prior GMP deficiency but now requests a new study, reversing prior acceptance of the single‑arm ALLELE study and creating an unexpected change after multi‑year dialogue. Pierre Fabre intends to engage the FDA with Atara Biotherapeutics and continue expanded access while pursuing a path toward accelerated approval.
Atara Biotherapeutics (Nasdaq: ATRA) announced the FDA issued a Complete Response Letter (CRL) on Jan 9, 2026 for the EBVALLO™ (tabelecleucel) BLA for EBV+ PTLD, stating the ALLELE single‑arm trial is no longer adequate for accelerated approval despite prior FDA alignment; GMP issues were resolved and no safety concerns were raised. Atara transferred the BLA to Pierre Fabre Pharmaceuticals in Nov 2025; PFP plans a Type A meeting expected within 45 days to seek a path to accelerated approval. Financially, cash and equivalents were approximately $8.5M as of Dec 31, 2025; milestone payments under amended commercialization terms were adjusted to $31M plus a potential $15M contingent payment. Atara implemented ~90% headcount reduction in 2025 and reduced ARC lease liability by ~65%.
Atara Biotherapeutics (Nasdaq: ATRA) reported Q3 2025 results and operational updates. The FDA accepted the BLA for tabelecleucel (tab-cel/Ebvallo) with Priority Review and a PDUFA target action date of January 10, 2026. Atara completed transfer of substantially all tab-cel activities and BLA sponsorship to Pierre Fabre, which would trigger a $40 million milestone payment upon FDA approval. Cash, cash equivalents and short-term investments were $13.7M as of September 30, 2025. Q3 net loss was $4.3M ($0.32/sh) versus $21.9M a year earlier; total revenues were $3.5M versus $40.2M in Q3 2024. Workforce reduced by ~29%, retaining ~15 employees.
Pierre Fabre Pharmaceuticals (ATRA) announced it has taken over the U.S. Biologics License Application (BLA) for tabelecleucel from Atara Biotherapeutics, making Pierre Fabre responsible for global clinical development, regulatory, commercial, and manufacturing activities for the therapy.
The BLA is under FDA Priority Review with a PDUFA target action date of January 10, 2026. The submission covers more than 430 patients, and if approved tabelecleucel would be indicated as monotherapy for patients aged two years and older with EBV+ PTLD after at least one prior therapy. Manufacturing for global development and commercial access is being performed by Pierre Fabre in the U.S.
Atara Biotherapeutics (Nasdaq: ATRA), a T-cell immunotherapy company, announced significant changes to its Board of Directors. Greg Ciongoli, founder of Adiumentum Capital Management and Director since 2024, has been appointed as Chair of the Board and will serve on the Nominating and Corporate Governance Committee.
The company also announced the departure of three board members: Pascal Touchon, Maria Grazia Roncarolo, M.D., and Ameet Mallik, as part of efforts to right-size the board following the company's reduced footprint. The changes come as Atara positions itself following FDA acceptance of its resubmitted BLA for Ebvallo, with focus on maximizing value from Ebvallo milestones and its allogeneic CAR T portfolio.